-
Trending Tickers: Cyclacel Pharmaceuticals (NASDAQ:CYCC), Loxo Oncology (NASDAQ:LOXO), Celladon Corporation (NASDAQ:CLDN), Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX), The McClatchy Company (NYSE:MNI)
On Friday shares of Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) closed at $0.81. Company’s sales growth for last 5 years was 13.60%. On May 12 Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) reported its financial results for the first quarter ended March 31, 2015. The Company’s net loss applicable to common shareholders for the first quarter ended March 31, 2015…
-
Moving Stocks: Twitter Inc (NYSE:TWTR), Loxo Oncology (NASDAQ:LOXO), Oracle Corporation (NYSE:ORCL), Pandora Media Inc (NYSE:P), Integrated Device Technology (NASDAQ:IDTI)
On Wednesday shares of Twitter Inc (NYSE:TWTR) closed at $37.26. Company’s EPS growth for next 5 years is recorded as 69.13%. Twitter Inc (NYSE:TWTR) has hired five new senior-level finance managers—including Todd Morgenfeld from Hewlett-Packard Co. and former Goldman Sachs Group Inc. executive Steve McGuinness—to streamline the teams reporting to Mr. Noto, according to people…
-
Watch List: Ambev S.A. (NYSE:ABEV), Loxo Oncology (NASDAQ:LOXO), Seattle Genetics (NASDAQ:SGEN), Inteliquent (NASDAQ:IQNT), SandRidge Energy (NYSE:SD)
On Thursday shares of Ambev S.A. (NYSE:ABEV) closed at $6.33. Company’s EPS growth for next 5 years is recorded as 5.04%. Fitch Ratings has affirmed Ambev S.A (NYSE:ABEV) as Foreign currency Long-term Issuer Default Rating (IDR) at ‘A’; and local currency Long-term IDR at ‘A’. Loxo Oncology, Inc. (NASDAQ:LOXO) in last trading activity decreased -6.27%…
-
Hot Stock List: NovaBay Pharmaceuticals (NYSEMKT:NBY), Loxo Oncology (NASDAQ:LOXO), InspireMD (NYSEMKT:NSPR), National Fuel Gas Company (NYSE:NFG), Optibase (NASDAQ:OBAS)
On Wednesday shares of NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY) closed at $0.73. Company’s sales growth for last 5 years was -41.20%. On 26 March, NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY) reported financial results for the three and 12 months ended December 31, 2014. NovaBay reported sales revenue of $385,000 for the quarter ended December 31, 2014, with gross…
-
Top Stocks: Pfizer Inc. (NYSE:PFE), Loxo Oncology (NASDAQ:LOXO), Petroleo Brasileiro Petrobras SA (ADR) (NYSE:PBR), HCP (NYSE:HCP), ASML Holding NV (NASDAQ:ASML)
Pfizer Inc. (NYSE:PFE) announced that the European Commission approved an expanded indication for the use of Prevenar 13 (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) for the prevention of pneumonia caused by the 13 pneumococcal serotypes in the vaccine in adults aged 18 years and older. On Wednesday shares of Pfizer Inc. (NYSE:PFE) closed at $34.64.…
-
What’s Hot: Loxo Oncology (NASDAQ:LOXO), Altisource Asset Management Corporation (NYSEMKT:AAMC), Wave Systems Corp. (NASDAQ:WAVX), Carriage Services Inc. (NYSE:CSV), HMS Holdings (NASDAQ:HMSY)
Loxo Oncology (Nasdaq: LOXO) provided updated 2015 program guidance and unveiled molecular targets for three of its active preclinical programs. The three targets disclosed are Rearranged during Transfection (RET), Fibroblast Growth Factor Receptor (FGFR), and FMS-Like Tyrosine kinase 3 (FLT3). In addition to these three programs, Loxo possesses well-vetted candidates for two other programs, not…
-
Morning Movers: Loxo Oncology (NASDAQ:LOXO), Bonanza Creek Energy (NYSE:BCEI), Valero Energy Corporation (NYSE:VLO), ARC Document Solutions (NYSE:ARC), Google Inc (NASDAQ:GOOG)
Loxo Oncology (NASDAQ:LOXO) has received a consensus broker rating score of 1.00 (Strong Buy) from the four analysts that provide coverage for the company, Zacks Investment Research reports. Four equities research analysts have rated the stock with a strong buy recommendation. On Friday shares of Loxo Oncology, Inc. (NASDAQ:LOXO) closed at $12.79. On January 20,…
-
Traders Are Watching: Loxo Oncology (NASDAQ:LOXO), Achillion Pharmaceuticals (NASDAQ:ACHN), Craft Brew Alliance (NASDAQ:BREW), Kimco Realty (NYSE:KIM), Arcos Dorados (NYSE:ARCO)
On October 28, Loxo Oncology, Inc. (Nasdaq:LOXO) a biopharmaceutical company focused on developing targeted cancer therapies for genetically-defined populations, announced the promotion of Jennifer Low, M.D., Ph.D. to Chief Medical Officer (CMO) and the appointment of Lori Kunkel, M.D. as a non-employee member of the Loxo Board of Directors. Loxo Oncology, Inc. (NASDAQ:LOXO) in last…